Medsafe, New Zealand’s regulatory authority, has granted provisional approval to the Janssen Covid-19 vaccine for individuals aged 18 years and older. According to ministers, the country secured two million doses of the Janssen vaccine through an advance purchase agreement in 2020. The Janssen Covid-19 vaccine has also received emergency or provisional approval in the USA, Canada, and Australia.

According to the Philippines Food and Drug Administration (FDA), the country will allow a 42-day interval between Russia’s Sputnik V Covid-19 vaccine doses, though it is still below the 90-day interval recommended by Russia’s Gamaleya Research Institute of Epidemiology and Microbiology, the vaccine manufacturer. FDA Chief Rolando Enrique Domingo stated that the Gamaleya Institute had recommended to widen the time interval between two vaccine doses from 21 days to 90 days to re-evaluate the vaccine’s efficacy.

PharmaJet, the needle-free injection technology maker, announced that its partner pharmaceutical company Zydus Cadila has submitted a request for emergency use authorisation to the office of the Drug Controller General of India for its plasmid DNA Covid-19 vaccine. The ZyCoV-D vaccine is expected to be exclusively administered using the PharmaJet Tropis needle-free device. This is the world’s first ever plasmid DNA vaccine for human use.